150 related articles for article (PubMed ID: 34614505)
1. ALL blasts drive primary mesenchymal stromal cells to increase asparagine availability during asparaginase treatment.
Chiu M; Taurino G; Dander E; Bardelli D; Fallati A; Andreoli R; Bianchi MG; Carubbi C; Pozzi G; Galuppo L; Mirandola P; Rizzari C; Tardito S; Biondi A; D'Amico G; Bussolati O
Blood Adv; 2021 Dec; 5(23):5164-5178. PubMed ID: 34614505
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.
Iwamoto S; Mihara K; Downing JR; Pui CH; Campana D
J Clin Invest; 2007 Apr; 117(4):1049-57. PubMed ID: 17380207
[TBL] [Abstract][Full Text] [Related]
3. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
[TBL] [Abstract][Full Text] [Related]
4. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
Blachier J; Cleret A; Guerin N; Gil C; Fanjat JM; Tavernier F; Vidault L; Gallix F; Rama N; Rossignol R; Piedrahita D; Andrivon A; Châlons-Cottavoz M; Aguera K; Gay F; Horand F; Laperrousaz B
Exp Cell Res; 2023 May; 426(2):113568. PubMed ID: 36967104
[TBL] [Abstract][Full Text] [Related]
5. Asparagine transport through SLC1A5/ASCT2 and SLC38A5/SNAT5 is essential for BCP-ALL cell survival and a potential therapeutic target.
Taurino G; Dander E; Chiu M; Pozzi G; Maccari C; Starace R; Silvestri D; Griffini E; Bianchi MG; Carubbi C; Andreoli R; Mirandola P; Valsecchi MG; Rizzari C; D'Amico G; Bussolati O
Br J Haematol; 2024 May; ():. PubMed ID: 38736325
[TBL] [Abstract][Full Text] [Related]
6. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine.
Ehsanipour EA; Sheng X; Behan JW; Wang X; Butturini A; Avramis VI; Mittelman SD
Cancer Res; 2013 May; 73(10):2998-3006. PubMed ID: 23585457
[TBL] [Abstract][Full Text] [Related]
7. IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase.
Laranjeira AB; de Vasconcellos JF; Sodek L; Spago MC; Fornazim MC; Tone LG; Brandalise SR; Nowill AE; Yunes JA
Leukemia; 2012 May; 26(5):1001-11. PubMed ID: 22005787
[TBL] [Abstract][Full Text] [Related]
8. Low expression of asparagine synthetase in lymphoid blasts precludes its role in sensitivity to L-asparaginase.
Hermanova I; Zaliova M; Trka J; Starkova J
Exp Hematol; 2012 Aug; 40(8):657-65. PubMed ID: 22542578
[TBL] [Abstract][Full Text] [Related]
9. Vincristine but not imatinib could suppress mesenchymal niche's support to lymphoid leukemic cells.
Fung KL; Liang RH; Chan GC
Leuk Lymphoma; 2010 Mar; 51(3):515-22. PubMed ID: 19925050
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
[TBL] [Abstract][Full Text] [Related]
11. Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells.
Aslanian AM; Kilberg MS
Biochem J; 2001 Aug; 358(Pt 1):59-67. PubMed ID: 11485552
[TBL] [Abstract][Full Text] [Related]
12. The
Taurino G; Chiu M; Bianchi MG; Griffini E; Bussolati O
Am J Physiol Cell Physiol; 2023 Aug; 325(2):C550-C562. PubMed ID: 37458433
[No Abstract] [Full Text] [Related]
13. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
Sindhu R; Manonmani HK
Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide loss-of-function genetic screening identifies opioid receptor μ1 as a key regulator of L-asparaginase resistance in pediatric acute lymphoblastic leukemia.
Kang SM; Rosales JL; Meier-Stephenson V; Kim S; Lee KY; Narendran A
Oncogene; 2017 Oct; 36(42):5910-5913. PubMed ID: 28650467
[TBL] [Abstract][Full Text] [Related]
15. Improving the Treatment of Acute Lymphoblastic Leukemia.
Radadiya A; Zhu W; Coricello A; Alcaro S; Richards NGJ
Biochemistry; 2020 Sep; 59(35):3193-3200. PubMed ID: 32786406
[TBL] [Abstract][Full Text] [Related]
16. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
17. Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability.
Chiu M; Toscani D; Marchica V; Taurino G; Costa F; Bianchi MG; Andreoli R; Franceschi V; Storti P; Burroughs-Garcia J; Eufemiese RA; Dalla Palma B; Campanini N; Martella E; Mancini C; Shan J; Kilberg MS; D'Amico G; Dander E; Agnelli L; Pruneri G; Donofrio G; Bussolati O; Giuliani N
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33167336
[TBL] [Abstract][Full Text] [Related]
18.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
19. L-Asparaginase delivery systems targeted to minimize its side-effects.
Talluri VP; Mutaliyeva B; Sharipova A; Ulaganathan V; Lanka SS; Aidarova S; Suigenbayeva A; Tleuova A
Adv Colloid Interface Sci; 2023 Jun; 316():102915. PubMed ID: 37159987
[TBL] [Abstract][Full Text] [Related]
20. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
Panosyan EH; Grigoryan RS; Avramis IA; Seibel NL; Gaynon PS; Siegel SE; Fingert HJ; Avramis VI
Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
